A partial phase out of a top insulin product by Danish drug maker Novo Nordisk may open a bounty for Eris Pharma and its ...

Chennai: Every Saturday, six specialists at the newly opened Teen Clinic at Rajiv Gandhi Govt General Hospital attend to ...

Speaking at the Irish Medical Organisation’s annual meeting in Killarney, Prof Barry pointed to what could be the “next big ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...